How GLP-1 Agonists Work in the Body

How GLP-1 agonists work in the body

GLP-1 is a hormone released from the gut around meals. It acts through the GLP-1 receptor, helping coordinate blood-glucose control and food intake. Natural GLP-1 is cleared quickly; medicines designed to activate its receptor can have longer effects. This page follows the signals through the body. For a discussion of what human studies actually prove, read the mechanism evidence analysis. Drucker, 2018 · Nauck et al., 2021

Semaglutide, the ingredient in Wegovy, selectively activates the GLP-1 receptor. Tirzepatide, the ingredient in Zepbound, activates both GIP and GLP-1 receptors. The overlapping GLP-1 action makes tirzepatide relevant to this explanation, but it is a dual agonist rather than a GLP-1-only medicine. These classifications come from the cited U.S. labels reviewed in September 2026. Wegovy label, section 12.1 · Zepbound label, section 12.1

1. Pancreas: insulin and glucagon

When blood glucose is higher, GLP-1 receptor signaling increases insulin release from pancreatic beta cells and reduces glucagon release. Insulin helps lower blood glucose; glucagon normally helps raise it. Wegovy’s semaglutide label describes both effects as glucose-dependent. Zepbound’s tirzepatide label describes glucose-dependent insulin secretion and reduced glucagon secretion. Drucker, 2018 · Wegovy label, section 12.2 · Zepbound label, section 12.2

Glucose dependence does not mean that low blood sugar is impossible. Both labels warn that using these products with insulin or an insulin secretagogue can increase hypoglycemia risk, including severe hypoglycemia. The label for the specific medicine and the person’s clinical situation govern that risk. Wegovy label, section 5.4 · Zepbound label, section 5.7

2. Gut: the timing of stomach emptying

GLP-1 signaling can slow the movement of food out of the stomach. Wegovy’s label reports delayed gastric emptying with semaglutide. Zepbound’s label reports the same effect with tirzepatide, and specifies that the delay is largest after the first dose and diminishes over time. Slower emptying is one part of the physiological picture; its contribution is not identical at every time point or for every product. Wegovy label, section 12.2 · Zepbound label, section 12.2 · Nauck et al., 2021

3. Appetite: signaling linked to food intake

GLP-1 receptors are present in brain areas involved in appetite regulation. Wegovy’s label says semaglutide decreases calorie intake, likely through effects on appetite. Zepbound’s label also reports decreased calorie intake with tirzepatide, while noting that evidence about added GIP effects on food-intake regulation is nonclinical. A receptor location or animal neuron experiment does not by itself establish the full pathway in a person. Wegovy label, sections 12.1–12.2 · Zepbound label, sections 12.1–12.2

Together, the pancreatic, gut, and appetite actions help explain why these medicines can affect glucose and body weight. They do not make every clinical benefit or safety outcome predictable from a diagram. For approved uses and warnings, the drug-class guide and each current product label provide the product-specific context. Wegovy label, sections 1, 5 and 12 · Zepbound label, sections 1, 5 and 12

Evidence grade: high for the labeled pharmacodynamic actions; the relative contribution of each pathway to a human outcome is not established. The cited mechanism reviews explain the biology; current FDA labels are the authority for these products’ U.S. pharmacology and warnings. This guide is educational and does not provide medical advice or treatment recommendations.

Sources & Citations

• 1

  regulatory

  WEGOVY (semaglutide) injection and tablets U.S. Prescribing Information (revised June 2026)

  fda-wegovy-label-2026-218316s007

• 2

  regulatory

  ZEPBOUND (tirzepatide) U.S. Prescribing Information (revised August 2026)

  fda-zepbound-label-2026-217806s041

• 3

  journal

  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

  pmid-29617641

• 4

  journal

  GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art

  pmid-33068776